Dishman Carbogen Amcis Limited – Investor Presentation Summary

Key Operational Highlights

  • Global team strength of 2,100+ members, with 950+ dedicated R&D scientists.
  • Operations span 13 countries including India, Switzerland, UK, France, China, and the Netherlands.
  • Strong basket of 14 molecules in Late Phase III development; 30 total commercialized molecules.
  • Successful first FDA Pre-Approval Inspection at its Vionnaz site.
  • Commencement of tech transfer of a second molecule from Switzerland to India.

Key drivers of operational performance: Lower development revenue in the CDMO segment and rescheduling of project deliverables.

Segment-wise Performance

  • CDMO Segment: Revenue of ₹9,290.4 mn in H1FY27, a decline of 17.1% YoY from ₹11,206.4 mn. Q2FY27 revenue was ₹3,887.5 mn, down 23.7% YoY.
  • Marketable Molecules Segment: Revenue of ₹2,559.7 mn in H1FY27, an increase of 6.6% YoY from ₹2,400.6 mn. Q2FY27 revenue was ₹1,186.2 mn.

Explanation of significant changes in segment performance: CDMO decline was due to lower development revenue and rescheduling of ~CHF 10 mn worth of projects to H2FY27. MM growth was driven by higher sales of Quaternary compounds, though offset by a decline in the vitamin segment.

Financial Highlights

  • Revenue: ₹11,850.1 mn (H1FY27)
  • EBITDA: ₹1,060.4 mn (H1FY27)
  • PAT: Net Loss of ₹(1,246.1) mn (H1FY27)
  • EPS: Not Specified
  • Margins: EBITDA Margin of 8.9% (H1FY27); PAT Margin of -10.5% (H1FY27)
  • YoY/QoQ comparison: H1FY27 Revenue down 12.9% YoY; H1FY27 PAT down 240.5% YoY.
  • Drivers of financial performance: Lower overall revenue, a higher contribution from lower-margin products, and a high fixed cost base.
  • Comparison to market estimates: Not Specified
  • Key Risks: Lower development revenue, product mix shift to lower-margin items, and project rescheduling.

Geographical Revenue Split

  • Domestic vs Export/Regional Revenue: Not Specified
  • Regional Breakdown: Not Specified

Balance Sheet Snapshot

  • Net Debt/Equity: Not Specified
  • Reserves: Other Equity of ₹66,397.1 mn (Sep-26)
  • Current Assets/Liabilities: Current Assets ₹30,138.1 mn; Current Liabilities ₹27,210.6 mn (Sep-26)
  • Working Capital/Leverage Metrics: Not Specified
  • Financial Health Insights: Cash and cash equivalents stood at ₹10,090.9 mn (Sep-26), up from ₹7,877.6 mn (Mar-26). Short-term borrowings increased to ₹16,319.4 mn from ₹12,405.4 mn.

Capex & Cash Flow Health

  • Capital Expenditure: Addition of USD 5.4 mn in Q2FY27; USD 10.3 mn in H1FY27.
  • Free Cash Flow: Not Specified
  • Operating Cash Flow: Not Specified
  • Net Debt Movement: Not Specified
  • Investment Rationale: Focus on capacity expansion and technology upgrades.

Strategic & R&D Initiatives

  • Investments in Innovation: 32 R&D and HIPO labs; 23 multi-purpose manufacturing facilities globally; a new 9,500 m2 sterile injectable facility in France.
  • Expected impact on growth: Not Specified
  • Strategic Rationale: Providing end-to-end integrated high-value niche CDMO offerings; strong integration between Dishman and Carbogen Amcis.

Industry Trends & Business Environment

  • Macro/Industry Trends: Oncology and obesity expected to lead global therapy spending growth; specialty medicines to represent 46% of global spending by 2029.
  • Impact on Company: Positions the company as an integrated CDMO player along the entire value chain.

Management Commentary & Growth Outlook

  • Strategic Outlook: Not Specified in the provided data.
  • FY Guidance: Not Specified
  • Market Share Targets: Not Specified
  • Risks and Opportunities: Not Specified